Protocol SP1055: A Phase 3B, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the effect of Rotigotine (the STUDY DRUG); on motor symptoms in patients with advanced Parkinsons disease with motor fluctuations and ga